Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

GLUE

Monte Rosa Therapeutics Inc

Feb 06 • 04:00PM ET

19.55

+0.65 3.44 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA BPMC FATE SRPT PTCT EXEL ADPT SGMO EDIT

| Held by: AVUV VTI IWM XBI VXF IWN IBB BSVO SCHA VTWO

Scroll to Statements

Index	RUT	P/E	64.01	EPS (ttm)	0.31	Insider Own	37.42%	Shs Outstand	61.79M	Perf Week	-4.73%
Market Cap	1.49B	Forward P/E	-	EPS next Y	-1.38	Insider Trans	-0.09%	Shs Float	47.71M	Perf Month	-16.02%
Enterprise Value	1.14B	PEG	-	EPS next Q	-0.33	Inst Own	61.21%	Short Float	11.64%	Perf Quarter	58.81%
Income	20.95M	P/S	8.21	EPS this Y	78.43%	Inst Trans	-5.52%	Short Ratio	3.48	Perf Half Y	362.17%
Sales	181.54M	P/B	4.91	EPS next Y	-553.52%	ROA	5.41%	Short Interest	5.55M	Perf YTD	24.68%
Book/sh	3.98	P/C	3.81	EPS next 5Y	-16.50%	ROE	9.28%	52W High	25.77 -24.14%	Perf Year	185.82%
Cash/sh	5.13	P/FCF	10.28	EPS past 3/5Y	14.78% -41.09%	ROIC	7.43%	52W Low	3.50 458.56%	Perf 3Y	170.40%
Dividend Est.	-	EV/EBITDA	67.66	Sales past 3/5Y	- -	Gross Margin	95.41%	Volatility	7.73% 6.61%	Perf 5Y	-
Dividend TTM	-	EV/Sales	6.28	EPS Y/Y TTM	116.97%	Oper. Margin	4.69%	ATR (14)	1.52	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.54	Sales Y/Y TTM	1112.27%	Profit Margin	11.54%	RSI (14)	44.94	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.54	EPS Q/Q	-12.99%	SMA20	-12.46%	Beta	1.63	Target Price	33.80
Payout	-	Debt/Eq	0.16	Sales Q/Q	38.54%	SMA50	2.31%	Rel Volume	0.85	Prev Close	18.90
Employees	134	LT Debt/Eq	0.15	Earnings	Nov 06 BMO	SMA200	100.03%	Avg Volume	1.60M	Price	19.55
IPO	Jun 24, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.91% 73.85%	Trades		Volume	1,358,761	Change	3.44%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$14 → $11
Feb-15-24	Initiated	Wedbush	Outperform	$11
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$18
Oct-13-22	Initiated	UBS	Buy	$22
Aug-15-22	Initiated	Jefferies	Buy	$20
Apr-28-22	Initiated	Credit Suisse	Neutral	$19
Feb-10-22	Initiated	Wells Fargo	Equal Weight	$19
Oct-14-21	Initiated	SVB Leerink	Mkt Perform	$20

Feb-05-26 11:37AM	3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher (MarketBeat)
Jan-16-26 08:39PM	Staar Surgical, Alumis, and More Stocks See Action From Activist Investors (Barrons.com)
Jan-08-26 10:49PM	Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering (GlobeNewswire) +8.72%
11:09AM	GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug (Zacks)
08:55AM	Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
04:01PM	Loading…
Jan-07-26 04:01PM	Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +45.41%
12:00PM	Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why (Zacks)
11:21AM	Stocks Hover Near Record Highs on Mixed US Economic News (Barchart)
10:07AM	Stocks Supported by Lower Bond Yields (Barchart)
07:00AM	Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects (GlobeNewswire)
Jan-06-26 04:05PM	Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results (GlobeNewswire) +11.18%
Dec-17-25 07:11AM	Monte Rosa Therapeutics announces data from Phase 1/2 study of MRT-2359 (TipRanks) -10.24%
Dec-16-25 04:22PM	Monte Rosa Scores A Win In Prostate Cancer, And Rockets To A Four-Year High (Investor's Business Daily) +13.43%
07:00AM	Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations (GlobeNewswire)
Dec-15-25 04:01PM	Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results (GlobeNewswire)
11:30AM	Loading…
Nov-08-25 11:30AM	Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases (GlobeNewswire)
Nov-06-25 08:30AM	Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.69%
07:34AM	Monte Rosa Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Nov-04-25 05:10PM	Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Nov-03-25 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.07%
Oct-24-25 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases (GlobeNewswire) +7.32%
Sep-30-25 11:42AM	Pallas Capital Backs Monte Rosa Therapeutics, Inc. (GLUE) Amid Growth Prospects (Insider Monkey)
Sep-16-25 09:49AM	Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis (Zacks) -6.64%
08:01AM	Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock? (Zacks)
Sep-15-25 12:31PM	Novartis returns to Monte Rosa for second time in a year with $5.7bn deal (Pharmaceutical Technology) +44.07%
08:24AM	Monte Rosa surges premarket on Novartis collaboration deal (Investing.com)
07:15AM	Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics (Reuters)
07:00AM	Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases (GlobeNewswire)
05:39AM	Novartis dives deeper into protein degraders with second Monte Rosa deal (BioPharma Dive)
07:00AM	Loading…
Sep-02-25 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-07-25 08:25AM	Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:22AM	Monte Rosa Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-06-25 06:00PM	Certara, Inc. (CERT) Q2 Earnings Miss Estimates (Zacks) -9.83%
Jul-22-25 07:30AM	Monte Rosa doses first subjects in trial of MRT-8102 for inflammatory conditions (Clinical Trials Arena)
Jul-21-25 07:00AM	Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases (GlobeNewswire)
Jul-03-25 02:15PM	Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines (GlobeNewswire)
Jun-11-25 08:38AM	Monte Rosa Therapeutics receives FDA clearance for MRT-8102 IND (Pharmaceutical Business Review)
Jun-10-25 07:00AM	Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases (GlobeNewswire)
Jun-09-25 09:55AM	Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet (Zacks)
May-28-25 07:00AM	Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-08-25 08:25AM	Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates (Zacks) +9.61%
07:21AM	Monte Rosa Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
May-06-25 08:20AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -10.69%
May-01-25 08:15AM	Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates (Zacks)
Apr-28-25 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer (GlobeNewswire)
Mar-24-25 04:46PM	Monte Rosa Therapeutics: Exercise Extreme Caution (SeekingAlpha)
Mar-21-25 12:04PM	Monte Rosa Therapeutics Inc (GLUE) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com) -17.85%
09:33AM	Mixed data results for two Monte Rosa molecular glue degraders (Clinical Trials Arena)
Mar-20-25 12:42PM	Monte Rosa to focus on prostate cancer only for oncology asset MRT-2359 (SeekingAlpha) +5.37%
12:00PM	Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript (SeekingAlpha)
10:35AM	Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates (Zacks)
07:00AM	Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs (GlobeNewswire)
Mar-11-25 07:00AM	Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 (GlobeNewswire)
Feb-24-25 07:00AM	Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -6.11%
Jan-11-25 07:27AM	Monte Rosa Therapeutics provide corporate update, key milestones 2025 (TipRanks)
Jan-10-25 07:00AM	Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025 (GlobeNewswire)
Jan-06-25 07:00AM	Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-13-24 07:00AM	Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors (GlobeNewswire)
Dec-11-24 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer (GlobeNewswire) -9.85%
07:00AM	Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders (GlobeNewswire)
Dec-06-24 07:11AM	Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study (TipRanks) +6.57%
Dec-05-24 07:00AM	Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors (GlobeNewswire)
Dec-02-24 05:44PM	Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High? (Zacks)
Nov-26-24 07:00AM	Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-15-24 09:55AM	Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet (Zacks) -8.73%
Nov-13-24 07:00AM	Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) -5.48%
Nov-07-24 08:35AM	Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Monte Rosa Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice (Zacks)
Oct-30-24 09:55AM	Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade (Zacks)
Oct-29-24 11:50AM	Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler (TipRanks)
10:57AM	Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis (GuruFocus.com)
Oct-28-24 05:40PM	Monte Rosa Almost Doubles Up 94% On A Massive Deal With Novartis (Investor's Business Daily) +93.87%
02:26PM	This Biotech Stock Has Doubled Its Value Today Here's Why (Investopedia)
02:10PM	Monte Rosa Stock Doubles Up 127% On A Massive Deal With Novartis (Investor's Business Daily)
08:53AM	Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs (Reuters)
08:46AM	Why Is Monte Rosa Therapeutics Stock Surging On Monday? (Benzinga)
07:33AM	Monte Rosa joins with Novartis in molecular glue drug deal (BioPharma Dive)
07:00AM	Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders (GlobeNewswire)
Oct-23-24 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors (GlobeNewswire) -8.29%
Aug-28-24 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.50%
Aug-19-24 07:00AM	Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study (GlobeNewswire)
Aug-08-24 08:15AM	Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +10.25%
07:15AM	Monte Rosa Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-08-24 08:36AM	Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day (GlobeNewswire) +6.87%
Jun-27-24 07:00AM	Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160 (GlobeNewswire) -8.40%
Jun-14-24 08:45AM	Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis (GlobeNewswire)
May-30-24 07:00AM	Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
07:00AM	Monte Rosa Therapeutics Announces Leadership Team Promotions (GlobeNewswire)
May-21-24 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease (GlobeNewswire) -13.23%
May-16-24 01:09PM	Monte Rosa Therapeutics Prices $100 Million Public Offering (MT Newswires)
07:00AM	Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering (GlobeNewswire)
May-15-24 04:01PM	Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
May-10-24 03:26PM	Monte Rosa Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview (GuruFocus.com) -6.37%
May-09-24 01:55PM	GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)

Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Warmuth Markus	President & CEO	Jan 07 '26	Sale	23.49	5,466	128,373	618,937	Jan 09 04:05 PM
Warmuth Markus	Officer	Jan 07 '26	Proposed Sale	23.49	5,466	128,372		Jan 07 04:58 PM
Nickson Philip	Chief Business & Legal Officer	Jan 05 '26	Sale	15.17	3,155	47,861	60,845	Jan 05 04:06 PM
Champoux Jennifer	Chief Operating Officer	Jan 05 '26	Sale	15.17	2,629	39,882	62,371	Jan 05 04:05 PM
Dunn Edmund	Principal Accounting Officer	Jan 05 '26	Sale	15.17	1,039	15,762	22,693	Jan 05 04:04 PM
Warmuth Markus	President & CEO	Jan 05 '26	Sale	15.17	10,135	153,748	624,403	Jan 05 04:04 PM
Janku Filip	Chief Medical Officer	Jan 05 '26	Sale	15.17	3,155	47,861	75,026	Jan 05 04:04 PM
Warmuth Markus	Officer	Jan 05 '26	Proposed Sale	15.17	10,135	153,759		Jan 05 04:01 PM
Dunn Edmund	Principal Accounting Officer	Jun 03 '25	Sale	4.45	2,062	9,174	23,732	Jun 04 04:15 PM
Leo Chandra P.	Director	Mar 24 '25	Buy	5.84	10,000	58,383	10,000	Mar 25 06:32 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GLUE

Monte Rosa Therapeutics Inc

Upgrade your FINVIZ experience